Clinical trial NCT05310591: Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
Official title: Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: B Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia, in Relapse
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2022-04-05
Enrollment: 26
Sex: ALL
Minimum age (years): 1
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Tisagenlecleucel (CTL019) is an anti-CD19 autologous Chimeric Antigen Receptor (CAR) T-cell therapy, which has shown dramatic early results in advanced ALLs. Early loss of B-cell aplasia (recovery of B-cells in marrow/ peripheral blood within 6 months after infusion), a marker of the loss or non-functionality of the CAR T-cells, is associated to a very high risk of relapse. A reinfusion of CTL019, even after Fludarabine-Cyclophosphamide reconditioning, frequently fails to induce further expansion as observed in UPENN studies and in the Robert Debré Hospital experience.

Non-persistence of CAR T-cells may be due to immune- mediated rejection or environment-mediated suppression of their growth. Evidence for increased PD-1 expression in CAR T-cells between infusion and peak expansion has been demonstrated in clinical samples.

Preclinical data and few clinical data support a role of PD- 1-PD-L1 blockade in improving the effectiveness of CAR T-cell therapy.

The objectives of this phase I/II study is to determine the safety, efficacy and feasibility of Nivolumab (Opdivo®)- an anti-PD1 treatment- combined to tisagenlecleucel in a cohort of relapsed or refractory B-ALL patients, aged 1-25 years old, previously treated by tisagenlecleucel (Kymriah®), with a demonstrated early loss of B-cell aplasia (within 6 months), a surrogate marker of the loss of CAR T-cells or their non- functionality.

More specifically, the main objectives are:

• In cohort 1 that includes patients with a MRD negative disease status combined to an early loss (within 6 months) of B-cell aplasia :

To determine the optimal starting time of Nivolumab (Opdivo®) in terms of safety and efficacy among 4 candidate time points (day 14, day 11, day 5, and day - 1).

• In cohort 2 that includes relapsed patients with an early loss (within 6 months) of B-cell aplasia :

To estimate the feasibility in terms of safety and efficacy of a very early start of nivolumab (day-1), prior to the reinfusion of tisagenlecleucel


Eligibility criteria: Inclusion Criteria:

* Patients aged from 1 to 25 years (pediatric and young adults) with a history of CD19+ relapsed or refractory B-ALL (any relapse after HSCT, 2nd relapse or later, refractory ALL).
* Patient must have a second tisagenlecleucel (Kymriah ®) product available
* Cohort 1: previously treated by tisagenlecleucel (Kymriah ®), and who present an early loss of B-cell aplasia defined by blood B lymphocytes \< 10 /mm3 and/ or \< 3% of total lymphocytes (\< 6 months after infusion) while still being in CR with undetectable MRD
* Cohort 2: previously treated by tisagenlecleucel (Kymriah ®), who present a loss of B-cell aplasia defined by blood B lymphocytes \< 10 /mm3 and/ or \< 3% of total lymphocytes and a CD19+ ALL detectable disease in the marrow and/or Blood
* Life expectancy \> 12 weeks.
* Karnofsky (age \> 16) Lansky (age \< 16) \> 70 at screening.
* No organ dysfunction
* Who have signed an informed consent
* Affiliation to social security or any health insurance (as a beneficiary or assignee)

Exclusion Criteria:

* Patient has received intervening therapy for leukemia after first tisagenlecleucel infusion (chemotherapy, anti leukemic immunotherapy, ITK, allogeneic HSCT).
* Patient has an active autoimmune disease requiring systemic treatment within the past 2 years.
* Patient has known history of, or any evidence of active, non-infectious pneumonitis.
* Patient has a history of non-infectious pneumonitis that required steroid or has current pneumonitis.
* Had receive prior therapy with an anti-PD1, Anti- PDL1 or anti-PDL2 agent.
* Patient has hypersensivity to pembrolizumab/ nivolumab or one of its excipients
* Patient has received a live vaccine injection within 45 days of planned start of study therapy.
* Patients with concomitant genetic syndromes associated with bone marrow failure states: such as patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome. Patients with Down syndrome will not be excluded.
* Patients with Burkitt's lymphoma/leukemia
* Prior malignancy, except carcinoma in situ of the skin or cervix treated with curative intent and with no evidence of active disease.
* Prior treatment with any gene therapy product except first tisagenlecleucel (Kymriah ®) injection.
* Prior treatment with any anti-CD19/anti-CD3 therapy, or any other anti-CD19 therapy, except for patients pre-treated with blinatumomab and/or tisagenlecleucel (Kymriah®)
* Prior anti-cancer monoclonal antibody within 4 weeks before starting the study.
* Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade1 or at baseline) from adverse events due to a previously administered agent.
* Active or latent hepatitis B or active hepatitis C (test within 8 weeks of Screening), or any uncontrolled infection at Screening.
* Human immunodeficiency virus (HIV) positive test within 8 weeks of Screening.
* Presence of grade 2 to 4 acute or extensive chronic GVHD.
* Active CNS involvement by malignancy, defined as CNS-3 per NCCN guidelines. Note: Patients with history of CNS disease that has been effectively treated will be eligible.
* Uncontrolled acute life threatening bacterial, viral or fungal infection at Screening.
* Previous or concurrent malignancy with the following exceptions:

  * Adequately treated basal cell or squamous cell carcinoma
  * in situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to the study.
  * A primary malignancy completely resected and in CR for ≥ 5 years
* Pregnant or lactating women (female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion)
* Patient with hypersensivity to Fludarabine and/or cyclophosphamide and/or tisagenlecleucel and/or nivolumab or one of their excipients.

Primary outcomes:
measure: Proportion of patients with limiting-toxicities
timeFrame: at day 28
measure: Efficacy assessed by Minimal residual disease (MRD) negative Complete remission (CR) and B cell aplasia.
timeFrame: at 3 months
Secondary outcomes:
measure: Incidence of B cell aplasia
timeFrame: at 6 months
measure: Increase of B cell aplasia duration compared to the previous one observed
timeFrame: up to 24 months
measure: Proportion of patients with Disease best response
timeFrame: up to three months
measure: Proportion of patients with Complete remission
timeFrame: at 1 month
measure: Proportion of patients with Complete remission
timeFrame: at 3 months
measure: Proportion of patients with Complete remission
timeFrame: at 6 months
measure: Proportion of patients with Complete remission
timeFrame: at 12 months
measure: Proportion of patients with Minimal residual disease
timeFrame: at 1 month
measure: Proportion of patients with Minimal residual disease
timeFrame: at 3 months
measure: Proportion of patients with Minimal residual disease
timeFrame: at 6 months
measure: Proportion of patients with Minimal residual disease
timeFrame: at 12 months
measure: Overall survival
timeFrame: at one year
measure: Overall survival
timeFrame: at 2 years
measure: Event Free Survival (EFS)
timeFrame: at 1 year
measure: Event Free Survival (EFS)
timeFrame: at 2 years
measure: Incidence of Grade 3 adverse events
timeFrame: up to 2 years
measure: Incidence of Grade 3, 4 or 5 nivolumab-related adverse events
timeFrame: up to 2 years
measure: Incidence of GVHD
timeFrame: up to one year
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: CHRU Bordeaux
city: Lille
country: France
facility: CHRU Lille
city: Lyon
country: France
facility: HCL - Lyon Sud
city: Lyon
country: France
facility: HCL
city: Lyon
country: France
facility: HCL
city: Marseille
country: France
facility: Hôpital pour enfants - La Timone
city: Montpellier
country: France
facility: CHU Montpellier - Hopital Arnaud de Villeneuve
city: Nancy
country: France
facility: CHU Nancy
city: Nantes
country: France
facility: CHU Nantes - Hopital Mère-enfants
city: Paris
country: France
facility: Robert Debre hospital
city: Paris
country: France
facility: Saint Louis hospital
city: Rouen
country: France
facility: CHU Rouen
city: Strasbourg
country: France
facility: CHRU Strasbourg
Study officials:
References: